SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

Home・Elenco Azioni・AB Science SA

AB Science SA

Chiusa

0.959

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.923

Massimo

0.961

Metriche Chiave
By Trading Economics
Entrata	8.8M 3.6M
Vendite	144K 659K
Margine di Profitto	549.317
Dipendenti	36
EBITDA	1.8M -727K

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-628K 68M
Apertura precedente	0.96
Chiusura precedente	0.959

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

1.426 / 1.448 Supporto e resistenza

AB Science SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mag 2026, 22:52 UTC

I principali Market Mover

Osisko Shares Fall on Planned Convertible Notes Offering

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mag 2026, 23:44 UTC

Utili

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mag 2026, 23:35 UTC

Discorsi di Mercato

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mag 2026, 23:30 UTC

Discorsi di Mercato

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mag 2026, 23:15 UTC

Discorsi di Mercato

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mag 2026, 23:14 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mag 2026, 23:02 UTC

Discorsi di Mercato

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 22:27 UTC

Discorsi di Mercato

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mag 2026, 22:14 UTC

Discorsi di Mercato

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mag 2026, 22:10 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mag 2026, 22:00 UTC

Utili

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mag 2026, 21:38 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mag 2026, 21:27 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mag 2026, 21:20 UTC

Utili

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mag 2026, 21:19 UTC

Utili

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mag 2026, 21:18 UTC

Utili

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mag 2026, 21:17 UTC

Utili

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mag 2026, 21:16 UTC

Utili

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Confronto tra pari

Modifica del prezzo

AB Science SA Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a AB Science SA - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.426 / 1.448Supporto e resistenza

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.